Orexigen® Therapeutics, Inc. (Nasdaq: OREX) announced that results from its COR-I trial of Contrave® were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration. Results show that patients taking Contrave were two to three times more likely to lose at least 5% or 10% of their body weight compared to those taking placebo, on both an intent-to-treat (ITT) and completers basis.
Many patients with obesity are at higher risk for diabetes and cardiovascular disease, so evaluating the impact of weight loss on markers of cardiovascular and metabolic risk was a key objective of the COR (Contrave Obesity Research) Phase 3 program. Results from COR-I showed that treatment with Contrave resulted in significant improvements over placebo in waist circumference, insulin resistance, HDL cholesterol, triglycerides, and hsCRP, which are well-known and accepted measures of cardiometabolic risk. Patients taking Contrave also showed significant improvements in patient-reported control of eating, including reduced food cravings and reduced difficulty resisting food cravings.
"The secondary health benefits of weight loss are critical to understanding the potential role of pharmacotherapy in managing overweight and obese patients," said Frank Greenway, M.D., Medical Director at the Pennington Center Outpatient Research Clinic and lead investigator for the study. "This study showed that treatment with Contrave has meaningful impact on markers of cardiometabolic risk, demonstrating its potential to be an important new approach to the treatment of obesity."
Additional findings from patients on Contrave32 (32mg naltrexone sustained release (SR)/360mg bupropion SR):